Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Clinical trial NCT01902173 · COMPLETED

Trial details

NCT number: NCT01902173
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hematopoietic and Lymphoid Cell Neoplasm Locally Advanced Malignant Solid Neoplasm Locally Advanced Melanoma Metastatic Malignant Solid Neoplasm Metastatic Melanoma Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Unresectable Malignant Solid Neoplasm Unresectable Melanoma

Start date: 2013-10-08
Primary completion: 2018-05-16
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.